Literature DB >> 21071931

In vivo evaluation method of the effect of nattokinase on carrageenan-induced tail thrombosis in a rat model.

Seitaro Kamiya1, Masayori Hagimori, Masayoshi Ogasawara, Masayuki Arakawa.   

Abstract

Thrombosis is characterized by congenital and acquired procatarxis. Nattokinase inhibits thrombus formation in vitro. However, in vivo evaluation of the therapeutic efficacy of nattokinase against thrombosis remains to be conducted. Subcutaneous nattokinase injections of 1 or 2 mg/ml were administered to the tails of rats. Subsequently, κ-carrageenan was intravenously administered to the tails at 12 h after nattokinase injections. The mean length of the infarcted regions in the tails of rats was significantly shorter in rats administered 2 mg/ml of nattokinase than those in control rats. Nattokinase exhibited significant prophylactic antithrombotic effects. Previously, the in vitro efficacy of nattokinase against thrombosis had been reported; now our study has revealed the in vivo efficacy of nattokinase against thrombosis.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071931     DOI: 10.1159/000321518

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  11 in total

Review 1.  Microbial production of nattokinase: current progress, challenge and prospect.

Authors:  Dongbo Cai; Chengjun Zhu; Shouwen Chen
Journal:  World J Microbiol Biotechnol       Date:  2017-04-04       Impact factor: 3.312

2.  Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator.

Authors:  Haiyu Guo; Young-Hwan Ban; Yeseul Cha; Eun Suk An; Jieun Choi; Da Woom Seo; Dongsun Park; Ehn-Kyoung Choi; Yun-Bae Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

3.  Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation.

Authors:  Ja-Young Jang; Tae-Su Kim; Jingmei Cai; Jihyun Kim; Youngeun Kim; Kyungha Shin; Kwang Sei Kim; Sung Kyeong Park; Sung-Pyo Lee; Ehn-Kyoung Choi; Man Hee Rhee; Yun-Bae Kim
Journal:  Lab Anim Res       Date:  2013-12-20

4.  Thrombus Degradation by Fibrinolytic Enzyme of Stenotrophomonas sp. Originated from Indonesian Soybean-Based Fermented Food on Wistar Rats.

Authors:  Florensia Nailufar; Raymond R Tjandrawinata; Maggy T Suhartono
Journal:  Adv Pharmacol Sci       Date:  2016-08-21

5.  Effects of fermented red bean extract on nephropathy in streptozocin-induced diabetic rats.

Authors:  Kung-Chi Chan; Kar-Eng Kok; Keh-Feng Huang; Yao-Lin Weng; Yun-Chin Chung
Journal:  Food Nutr Res       Date:  2020-12-22       Impact factor: 3.894

6.  The Effect of Lactic Acid Bacteria-fermented Soybean Milk Products on Carrageenan-induced Tail Thrombosis in Rats.

Authors:  Seitaro Kamiya; Masayoshi Ogasawara; Masayuki Arakawa; Masayori Hagimori
Journal:  Biosci Microbiota Food Health       Date:  2013-07-25

7.  Statistical optimization of fibrinolytic enzyme production using agroresidues by Bacillus cereus IND1 and its thrombolytic activity in vitro.

Authors:  Ponnuswamy Vijayaraghavan; Samuel Gnana Prakash Vincent
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

Review 8.  Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases.

Authors:  Hongjie Chen; Eileen M McGowan; Nina Ren; Sara Lal; Najah Nassif; Fatima Shad-Kaneez; Xianqin Qu; Yiguang Lin
Journal:  Biomark Insights       Date:  2018-07-05

9.  Safety assessment of subtilisin QK in rats.

Authors:  Shuai Xiao; Dingbang Hu; Ya Gao; Yang Ai; Sang Luo; Song Chen; Ben Wang; Li Zhou; Yanshan Dong; Yefu Wang
Journal:  BMC Pharmacol Toxicol       Date:  2021-06-26       Impact factor: 2.483

10.  Heterologous expression of nattokinase from B. subtilis natto using Pichia pastoris GS115 and assessment of its thrombolytic activity.

Authors:  Zhai Chao; Wang Yaping; Yan Guangbo; Shu Min; Shen Wei; Ma Lixin; Huang Zunxi
Journal:  BMC Biotechnol       Date:  2021-08-09       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.